Moderna and Merck report positive trial results for experimental melanoma vaccine

Moderna and Merck announced encouraging preliminary results from a trial of their experimental vaccine for melanoma, a type of skin cancer. The vaccine, combined with Merck's Keytruda, aims to reduce cancer recurrence and metastasis.